#cardiovascular risk

1 story

#analyst targets #eli lilly #fda approval #forward p/e #investor expectations #mounjaro #novo nordisk #retatrutide #revenue growth #stock price #zepbound

Eli Lilly's $1500 Target Surprises Wall Street
Eli Lilly's revenue growth outpaces stock price, with analysts missing a $1500 target by 2027
24/7 Wall St. · 1m